BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Lefere S, Tacke F. Macrophages in obesity and non-alcoholic fatty liver disease: Crosstalk with metabolism. JHEP Rep. 2019;1:30-43. [PMID: 32149275 DOI: 10.1016/j.jhepr.2019.02.004] [Cited by in Crossref: 68] [Cited by in F6Publishing: 70] [Article Influence: 22.7] [Reference Citation Analysis]
Number Citing Articles
1 Liou CJ, Wu SJ, Shen SC, Chen LC, Chen YL, Huang WC. Phloretin ameliorates hepatic steatosis through regulation of lipogenesis and Sirt1/AMPK signaling in obese mice. Cell Biosci 2020;10:114. [PMID: 33014333 DOI: 10.1186/s13578-020-00477-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
2 De Muynck K, Vanderborght B, Van Vlierberghe H, Devisscher L. The Gut-Liver Axis in Chronic Liver Disease: A Macrophage Perspective. Cells 2021;10:2959. [PMID: 34831182 DOI: 10.3390/cells10112959] [Reference Citation Analysis]
3 Lotersztajn S, Riva A, Wang S, Dooley S, Chokshi S, Gao B. Inflammation in alcohol-associated liver disease progression. Z Gastroenterol 2022;60:58-66. [PMID: 35042254 DOI: 10.1055/a-1714-9246] [Reference Citation Analysis]
4 Powell EE, Wong VW, Rinella M. Non-alcoholic fatty liver disease. Lancet 2021;397:2212-24. [PMID: 33894145 DOI: 10.1016/S0140-6736(20)32511-3] [Cited by in Crossref: 12] [Cited by in F6Publishing: 3] [Article Influence: 12.0] [Reference Citation Analysis]
5 Cimini FA, Barchetta I, Ciccarelli G, Leonetti F, Silecchia G, Chiappetta C, Di Cristofano C, Capoccia D, Bertoccini L, Ceccarelli V, Carletti R, Fraioli A, Baroni MG, Morini S, Cavallo MG. Adipose tissue remodelling in obese subjects is a determinant of presence and severity of fatty liver disease. Diabetes Metab Res Rev 2021;37:e3358. [PMID: 32469428 DOI: 10.1002/dmrr.3358] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 6.0] [Reference Citation Analysis]
6 Luci C, Bourinet M, Leclère PS, Anty R, Gual P. Chronic Inflammation in Non-Alcoholic Steatohepatitis: Molecular Mechanisms and Therapeutic Strategies. Front Endocrinol (Lausanne) 2020;11:597648. [PMID: 33384662 DOI: 10.3389/fendo.2020.597648] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
7 Kragh Petersen S, Bilkei-Gorzo O, Govaere O, Härtlova A. Macrophages and scavenger receptors in obesity-associated non-alcoholic liver fatty disease (NAFLD). Scand J Immunol 2020;92:e12971. [PMID: 32892401 DOI: 10.1111/sji.12971] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
8 Metawea MI, Yousif WI, Moheb I. COVID 19 and liver: An A-Z literature review. Dig Liver Dis. 2021;53:146-152. [PMID: 32988758 DOI: 10.1016/j.dld.2020.09.010] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 11.0] [Reference Citation Analysis]
9 Amin M. COVID-19 and the liver: overview. Eur J Gastroenterol Hepatol 2021;33:309-11. [PMID: 32558697 DOI: 10.1097/MEG.0000000000001808] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]
10 Wang Q, Zhou XL, Mei GH, Wang J, Yu Z, Hu Y, Guo X, Zhang H, Xu X, He C, Guo J, Tao Y, Zhou H. Serum Heparanase: A New Clinical Biomarker Involved in Senile Metabolic Inflammatory Syndrome. Diabetes Metab Syndr Obes 2021;14:3221-8. [PMID: 34285529 DOI: 10.2147/DMSO.S291612] [Reference Citation Analysis]
11 Shroff T, Aina K, Maass C, Cipriano M, Lambrecht J, Tacke F, Mosig A, Loskill P. Studying metabolism with multi-organ chips: new tools for disease modelling, pharmacokinetics and pharmacodynamics. Open Biol 2022;12:210333. [PMID: 35232251 DOI: 10.1098/rsob.210333] [Reference Citation Analysis]
12 Tiegs G, Horst AK. TNF in the liver: targeting a central player in inflammation. Semin Immunopathol 2022. [PMID: 35122118 DOI: 10.1007/s00281-022-00910-2] [Reference Citation Analysis]
13 Licata A, Minissale MG, Distefano M, Montalto G. Liver injury, SARS-COV-2 infection and COVID-19: What physicians should really know? GastroHep 2021;3:121-30. [PMID: 34149320 DOI: 10.1002/ygh2.455] [Reference Citation Analysis]
14 Lefere S, Onghena L, Vanlander A, van Nieuwenhove Y, Devisscher L, Geerts A. Bariatric surgery and the liver-Mechanisms, benefits, and risks. Obes Rev 2021;22:e13294. [PMID: 34002452 DOI: 10.1111/obr.13294] [Reference Citation Analysis]
15 Cremonese C, Schierwagen R, Uschner FE, Torres S, Tyc O, Ortiz C, Schulz M, Queck A, Kristiansen G, Bader M, Sauerbruch T, Weiskirchen R, Walther T, Trebicka J, Klein S. Short-Term Western Diet Aggravates Non-Alcoholic Fatty Liver Disease (NAFLD) With Portal Hypertension in TGR(mREN2)27 Rats. Int J Mol Sci 2020;21:E3308. [PMID: 32392802 DOI: 10.3390/ijms21093308] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
16 Kern P, Balzer NR, Blank N, Cygon C, Wunderling K, Bender F, Frolov A, Sowa JP, Bonaguro L, Ulas T, Homrich M, Kiermaier E, Thiele C, Schultze JL, Canbay A, Bauer R, Mass E. Creld2 function during unfolded protein response is essential for liver metabolism homeostasis. FASEB J 2021;35:e21939. [PMID: 34549824 DOI: 10.1096/fj.202002713RR] [Reference Citation Analysis]
17 Khanna S, Parikh NS, VanWagner LB. Fatty liver and cerebrovascular disease: plausible association and possible mechanisms. Curr Opin Lipidol 2022;33:31-8. [PMID: 34799486 DOI: 10.1097/MOL.0000000000000799] [Reference Citation Analysis]
18 Wculek SK, Dunphy G, Heras-Murillo I, Mastrangelo A, Sancho D. Metabolism of tissue macrophages in homeostasis and pathology. Cell Mol Immunol 2021. [PMID: 34876704 DOI: 10.1038/s41423-021-00791-9] [Reference Citation Analysis]
19 Eswaran S, Babbar A, Drescher HK, Hitch TCA, Clavel T, Muschaweck M, Ritz T, Kroy DC, Trautwein C, Wagner N, Schippers A. Upregulation of Anti-Oxidative Stress Response Improves Metabolic Changes in L-Selectin-Deficient Mice but Does Not Prevent NAFLD Progression or Fecal Microbiota Shifts. Int J Mol Sci 2021;22:7314. [PMID: 34298930 DOI: 10.3390/ijms22147314] [Reference Citation Analysis]
20 Lefere S, Puengel T, Hundertmark J, Penners C, Frank AK, Guillot A, de Muynck K, Heymann F, Adarbes V, Defrêne E, Estivalet C, Geerts A, Devisscher L, Wettstein G, Tacke F. Differential effects of selective- and pan-PPAR agonists on experimental steatohepatitis and hepatic macrophages. J Hepatol 2020;73:757-70. [PMID: 32360434 DOI: 10.1016/j.jhep.2020.04.025] [Cited by in Crossref: 31] [Cited by in F6Publishing: 30] [Article Influence: 15.5] [Reference Citation Analysis]
21 Demirbaş F, Çaltepe G, Comba A, Abbasguliyev H, Yurttan Uyar N, Kalaycı AG. Association of obesity and non-alcoholic fatty liver disease with the fecal calprotectin level in children. Arab J Gastroenterol 2020;21:211-5. [PMID: 33248976 DOI: 10.1016/j.ajg.2020.09.003] [Reference Citation Analysis]
22 Bourgeois T, Jalil A, Thomas C, Magnani C, Le Guern N, Gautier T, Pais de Barros JP, Bergas V, Choubley H, Mazzeo L, Menegaut L, Josiane Lebrun L, Van Dongen K, Xolin M, Jourdan T, Buch C, Labbé J, Saas P, Lagrost L, Masson D, Grober J. Deletion of lysophosphatidylcholine acyltransferase 3 in myeloid cells worsens hepatic steatosis after a high-fat diet. J Lipid Res 2020;62:100013. [PMID: 33518513 DOI: 10.1194/jlr.RA120000737] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
23 Li R, Wang C, Chen Y, Li N, Wang Q, Zhang M, He C, Chen H. A combined network pharmacology and molecular biology approach to investigate the active ingredients and potential mechanisms of mulberry (Morus alba L.) leaf on obesity. Phytomedicine 2021;92:153714. [PMID: 34508977 DOI: 10.1016/j.phymed.2021.153714] [Reference Citation Analysis]
24 Lefere S, Devisscher L, Tacke F. Targeting CCR2/5 in the treatment of nonalcoholic steatohepatitis (NASH) and fibrosis: opportunities and challenges. Expert Opin Investig Drugs 2020;29:89-92. [PMID: 31952447 DOI: 10.1080/13543784.2020.1718106] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 5.5] [Reference Citation Analysis]
25 Luci C, Vieira E, Bourinet M, Rousseau D, Bonnafous S, Patouraux S, Lefevre L, Larbret F, Prod'homme V, Iannelli A, Tran A, Anty R, Bailly-Maitre B, Deckert M, Gual P. SYK-3BP2 Pathway Activity in Parenchymal and Myeloid Cells Is a Key Pathogenic Factor in Metabolic Steatohepatitis. Cell Mol Gastroenterol Hepatol 2021;13:173-91. [PMID: 34411785 DOI: 10.1016/j.jcmgh.2021.08.004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
26 Gaspar R, Castelo Branco C, Macedo G. Liver and COVID-19: From care of patients with liver diseases to liver injury. World J Hepatol 2021; 13(10): 1367-1377 [PMID: 34786172 DOI: 10.4254/wjh.v13.i10.1367] [Reference Citation Analysis]
27 de Andrade BZ, Zazula MF, Bittencourt Guimarães AT, Sagae Schneider SC, Boaretto ML, Felicio Poncio AC, Hoff Nunes Maciel JI, de Oliveira CMT, Costa RM, Flor Bertolini GR, Chasko Ribeiro LF. Whole-body vibration promotes lipid mobilization in hypothalamic obesity rat. Tissue Cell 2021;68:101456. [PMID: 33202347 DOI: 10.1016/j.tice.2020.101456] [Reference Citation Analysis]
28 Bae CR, Zhang H, Kwon YG. The endothelial dysfunction blocker CU06-1004 ameliorates choline-deficient L-amino acid diet-induced non-alcoholic steatohepatitis in mice. PLoS One 2020;15:e0243497. [PMID: 33275637 DOI: 10.1371/journal.pone.0243497] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
29 Thibaut R, Gage MC, Pineda-Torra I, Chabrier G, Venteclef N, Alzaid F. Liver macrophages and inflammation in physiology and physiopathology of non-alcoholic fatty liver disease. FEBS J 2021. [PMID: 33860630 DOI: 10.1111/febs.15877] [Reference Citation Analysis]
30 Ozkurt Z, Çınar Tanrıverdi E. COVID-19: Gastrointestinal manifestations, liver injury and recommendations. World J Clin Cases 2022; 10(4): 1140-1163 [DOI: 10.12998/wjcc.v10.i4.1140] [Reference Citation Analysis]
31 Dewidar B, Kahl S, Pafili K, Roden M. Metabolic liver disease in diabetes - From mechanisms to clinical trials. Metabolism 2020;111S:154299. [PMID: 32569680 DOI: 10.1016/j.metabol.2020.154299] [Cited by in Crossref: 17] [Cited by in F6Publishing: 20] [Article Influence: 8.5] [Reference Citation Analysis]
32 Bertolini A, van de Peppel IP, Bodewes FAJA, Moshage H, Fantin A, Farinati F, Fiorotto R, Jonker JW, Strazzabosco M, Verkade HJ, Peserico G. Abnormal Liver Function Tests in Patients With COVID-19: Relevance and Potential Pathogenesis. Hepatology 2020;72:1864-72. [PMID: 32702162 DOI: 10.1002/hep.31480] [Cited by in Crossref: 116] [Cited by in F6Publishing: 95] [Article Influence: 58.0] [Reference Citation Analysis]
33 Kumar M, Toprakhisar B, Van Haele M, Antoranz A, Boon R, Chesnais F, De Smedt J, Tricot T, Idoype TI, Canella M, Tilliole P, De Boeck J, Bajaj M, Ranga A, Bosisio FM, Roskams T, van Grunsven LA, Verfaillie CM. A fully defined matrix to support a pluripotent stem cell derived multi-cell-liver steatohepatitis and fibrosis model. Biomaterials 2021;276:121006. [PMID: 34304139 DOI: 10.1016/j.biomaterials.2021.121006] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
34 Mohamed MS, Ghaly S, Azmy KH, Mohamed GA. Assessment of interleukin 32 as a novel biomarker for non-alcoholic fatty liver disease. Egypt Liver Journal 2022;12. [DOI: 10.1186/s43066-022-00189-w] [Reference Citation Analysis]
35 Hachiya R, Tanaka M, Itoh M, Suganami T. Molecular mechanism of crosstalk between immune and metabolic systems in metabolic syndrome. Inflamm Regen 2022;42:13. [PMID: 35490239 DOI: 10.1186/s41232-022-00198-7] [Reference Citation Analysis]
36 de Gregorio E, Colell A, Morales A, Marí M. Relevance of SIRT1-NF-κB Axis as Therapeutic Target to Ameliorate Inflammation in Liver Disease. Int J Mol Sci 2020;21:E3858. [PMID: 32485811 DOI: 10.3390/ijms21113858] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 5.0] [Reference Citation Analysis]
37 Cheon SY, Cho K. Lipid metabolism, inflammation, and foam cell formation in health and metabolic disorders: targeting mTORC1. J Mol Med (Berl) 2021. [PMID: 34312684 DOI: 10.1007/s00109-021-02117-8] [Reference Citation Analysis]
38 Scheithauer TPM, Rampanelli E, Nieuwdorp M, Vallance BA, Verchere CB, van Raalte DH, Herrema H. Gut Microbiota as a Trigger for Metabolic Inflammation in Obesity and Type 2 Diabetes. Front Immunol 2020;11:571731. [PMID: 33178196 DOI: 10.3389/fimmu.2020.571731] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 6.0] [Reference Citation Analysis]
39 Rosa Neto JC, Calder PC, Curi R, Newsholme P, Sethi JK, Silveira LS. The Immunometabolic Roles of Various Fatty Acids in Macrophages and Lymphocytes. Int J Mol Sci 2021;22:8460. [PMID: 34445165 DOI: 10.3390/ijms22168460] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
40 Hupa-Breier KL, Dywicki J, Hartleben B, Wellhöner F, Heidrich B, Taubert R, Mederacke YE, Lieber M, Iordanidis K, Manns MP, Wedemeyer H, Hardtke-Wolenski M, Jaeckel E. Dulaglutide Alone and in Combination with Empagliflozin Attenuate Inflammatory Pathways and Microbiome Dysbiosis in a Non-Diabetic Mouse Model of NASH. Biomedicines 2021;9:353. [PMID: 33808404 DOI: 10.3390/biomedicines9040353] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
41 Tanase DM, Gosav EM, Costea CF, Ciocoiu M, Lacatusu CM, Maranduca MA, Ouatu A, Floria M. The Intricate Relationship between Type 2 Diabetes Mellitus (T2DM), Insulin Resistance (IR), and Nonalcoholic Fatty Liver Disease (NAFLD).J Diabetes Res. 2020;2020:3920196. [PMID: 32832560 DOI: 10.1155/2020/3920196] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 6.0] [Reference Citation Analysis]
42 Dixon ED, Nardo AD, Claudel T, Trauner M. The Role of Lipid Sensing Nuclear Receptors (PPARs and LXR) and Metabolic Lipases in Obesity, Diabetes and NAFLD. Genes (Basel) 2021;12:645. [PMID: 33926085 DOI: 10.3390/genes12050645] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
43 Ghallab A, Myllys M, Friebel A, Duda J, Edlund K, Halilbasic E, Vucur M, Hobloss Z, Brackhagen L, Begher-Tibbe B, Hassan R, Burke M, Genc E, Frohwein LJ, Hofmann U, Holland CH, González D, Keller M, Seddek AL, Abbas T, Mohammed ESI, Teufel A, Itzel T, Metzler S, Marchan R, Cadenas C, Watzl C, Nitsche MA, Kappenberg F, Luedde T, Longerich T, Rahnenführer J, Hoehme S, Trauner M, Hengstler JG. Spatio-Temporal Multiscale Analysis of Western Diet-Fed Mice Reveals a Translationally Relevant Sequence of Events during NAFLD Progression. Cells 2021;10:2516. [PMID: 34685496 DOI: 10.3390/cells10102516] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
44 Ji D, Xu J, Qin E, Zhang D, Cheng G, Wang Y, Lau G. Reply to: 'No evidence for an increased liver uptake of SARS-CoV-2 in metabolic-associated fatty liver disease'. J Hepatol. 2020;73:718-719. [PMID: 32387073 DOI: 10.1016/j.jhep.2020.04.039] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
45 Lamadrid P, Alonso-Peña M, San Segundo D, Arias-Loste M, Crespo J, Lopez-Hoyos M. Innate and Adaptive Immunity Alterations in Metabolic Associated Fatty Liver Disease and Its Implication in COVID-19 Severity. Front Immunol 2021;12:651728. [PMID: 33859644 DOI: 10.3389/fimmu.2021.651728] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
46 Sharma P, Kumar A, Anikhindi S, Bansal N, Singla V, Shivam K, Arora A. Effect of COVID-19 on Pre-existing Liver disease: What Hepatologist Should Know? J Clin Exp Hepatol 2021;11:484-93. [PMID: 33398223 DOI: 10.1016/j.jceh.2020.12.006] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
47 Roohani S, Tacke F. Liver Injury and the Macrophage Issue: Molecular and Mechanistic Facts and Their Clinical Relevance. Int J Mol Sci 2021;22:7249. [PMID: 34298870 DOI: 10.3390/ijms22147249] [Reference Citation Analysis]
48 Hu X, Sun L, Guo Z, Wu C, Yu X, Li J. Management of COVID-19 Patients with Chronic Liver Diseases and Liver Transplants. Ann Hepatol 2021;:100653. [PMID: 34929350 DOI: 10.1016/j.aohep.2021.100653] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
49 Çoraplı M, Çil E, Oktay C, Kaçmaz H, Çoraplı G, Bulut HT. Role of hepatosteatosis in the prognosis of COVID 19 disease. Clin Imaging 2021;80:1-5. [PMID: 34214871 DOI: 10.1016/j.clinimag.2021.06.034] [Reference Citation Analysis]
50 Ji D, Qin E, Xu J, Zhang D, Cheng G, Wang Y, Lau G. Non-alcoholic fatty liver diseases in patients with COVID-19: A retrospective study. J Hepatol 2020;73:451-3. [PMID: 32278005 DOI: 10.1016/j.jhep.2020.03.044] [Cited by in Crossref: 191] [Cited by in F6Publishing: 185] [Article Influence: 95.5] [Reference Citation Analysis]
51 Napodano C, Pocino K, Stefanile A, Marino M, Miele L, Gulli F, Basile V, Pandolfi F, Gasbarrini A, Rapaccini GL, Basile U. COVID-19 and hepatic involvement: The liver as a main actor of the pandemic novel. Scand J Immunol. 2021;93:e12977. [PMID: 32931622 DOI: 10.1111/sji.12977] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
52 Schwabe RF, Tabas I, Pajvani UB. Mechanisms of Fibrosis Development in Nonalcoholic Steatohepatitis. Gastroenterology 2020;158:1913-28. [PMID: 32044315 DOI: 10.1053/j.gastro.2019.11.311] [Cited by in Crossref: 47] [Cited by in F6Publishing: 53] [Article Influence: 23.5] [Reference Citation Analysis]
53 Laurindo CP, Rego Gregorio KC, Rippi Moreno AC, Viudes Agostinho JM, Campos EC, Nai GA, Nunes MT, Seraphim PM. Resistance training mitigates hepato-cardiac changes and muscle mitochondrial protein reductions in rats with diet-induced obesity. Heliyon 2021;7:e08374. [PMID: 34841103 DOI: 10.1016/j.heliyon.2021.e08374] [Reference Citation Analysis]
54 Degroote H, Lefere S, Vandierendonck A, Vanderborght B, Meese T, Van Nieuwerburgh F, Verhelst X, Geerts A, Van Vlierberghe H, Devisscher L. Characterization of the inflammatory microenvironment and hepatic macrophage subsets in experimental hepatocellular carcinoma models. Oncotarget 2021;12:562-77. [PMID: 33796224 DOI: 10.18632/oncotarget.27906] [Reference Citation Analysis]
55 Francque S, Szabo G, Abdelmalek MF, Byrne CD, Cusi K, Dufour J, Roden M, Sacks F, Tacke F. Nonalcoholic steatohepatitis: the role of peroxisome proliferator-activated receptors. Nat Rev Gastroenterol Hepatol 2021;18:24-39. [DOI: 10.1038/s41575-020-00366-5] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 11.0] [Reference Citation Analysis]
56 Singh A, Hussain S, Antony B. Non-alcoholic fatty liver disease and clinical outcomes in patients with COVID-19: A comprehensive systematic review and meta-analysis. Diabetes Metab Syndr 2021;15:813-22. [PMID: 33862417 DOI: 10.1016/j.dsx.2021.03.019] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
57 Trauner M, Fuchs CD. Novel therapeutic targets for cholestatic and fatty liver disease. Gut 2022;71:194-209. [PMID: 34615727 DOI: 10.1136/gutjnl-2021-324305] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 6.0] [Reference Citation Analysis]
58 Ibáñez-Samaniego L, Bighelli F, Usón C, Caravaca C, Fernández Carrillo C, Romero M, Barreales M, Perelló C, Madejón A, Marcos AC, Albillos A, Fernández I, García-Samaniego J, Calleja JL, Bañares R. Elevation of Liver Fibrosis Index FIB-4 Is Associated With Poor Clinical Outcomes in Patients With COVID-19.J Infect Dis. 2020;222:726-733. [PMID: 32563190 DOI: 10.1093/infdis/jiaa355] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 9.0] [Reference Citation Analysis]
59 Mills EL, Harmon C, Jedrychowski MP, Xiao H, Garrity R, Tran NV, Bradshaw GA, Fu A, Szpyt J, Reddy A, Prendeville H, Danial NN, Gygi SP, Lynch L, Chouchani ET. UCP1 governs liver extracellular succinate and inflammatory pathogenesis. Nat Metab 2021;3:604-17. [PMID: 34002097 DOI: 10.1038/s42255-021-00389-5] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
60 Qing J, Zhang Z, Novák P, Zhao G, Yin K. Mitochondrial metabolism in regulating macrophage polarization: an emerging regulator of metabolic inflammatory diseases. Acta Biochim Biophys Sin (Shanghai) 2020;52:917-26. [PMID: 32785581 DOI: 10.1093/abbs/gmaa081] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 5.5] [Reference Citation Analysis]
61 Gilgenkrantz H, Mallat A, Moreau R, Lotersztajn S. Targeting cell-intrinsic metabolism for antifibrotic therapy. J Hepatol 2021;74:1442-54. [PMID: 33631228 DOI: 10.1016/j.jhep.2021.02.012] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
62 Dallio M, Sangineto M, Romeo M, Villani R, Romano AD, Loguercio C, Serviddio G, Federico A. Immunity as Cornerstone of Non-Alcoholic Fatty Liver Disease: The Contribution of Oxidative Stress in the Disease Progression. Int J Mol Sci 2021;22:E436. [PMID: 33406763 DOI: 10.3390/ijms22010436] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 8.0] [Reference Citation Analysis]
63 Vila-Bedmar R, Cruces-Sande M, Arcones AC, Willemen HLDM, Prieto P, Moreno-Indias I, Díaz-Rodríguez D, Francisco S, Jaén RI, Gutiérrez-Repiso C, Heijnen CJ, Boscá L, Fresno M, Kavelaars A, Mayor F Jr, Murga C. GRK2 levels in myeloid cells modulate adipose-liver crosstalk in high fat diet-induced obesity. Cell Mol Life Sci 2020;77:4957-76. [PMID: 31927610 DOI: 10.1007/s00018-019-03442-5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
64 Ma R, Zhan Y, Zhang Y, Wu L, Wang X, Guo M. Schisandrin B ameliorates non-alcoholic liver disease through anti-inflammation activation in diabetic mice. Drug Dev Res 2021. [PMID: 34927282 DOI: 10.1002/ddr.21905] [Reference Citation Analysis]
65 Lei L, Ei Mourabit H, Housset C, Cadoret A, Lemoinne S. Role of Angiogenesis in the Pathogenesis of NAFLD. J Clin Med 2021;10:1338. [PMID: 33804956 DOI: 10.3390/jcm10071338] [Reference Citation Analysis]
66 Batchuluun B, Pinkosky SL, Steinberg GR. Lipogenesis inhibitors: therapeutic opportunities and challenges. Nat Rev Drug Discov 2022. [PMID: 35031766 DOI: 10.1038/s41573-021-00367-2] [Reference Citation Analysis]
67 Alharthi J, Latchoumanin O, George J, Eslam M. Macrophages in metabolic associated fatty liver disease. World J Gastroenterol 2020; 26(16): 1861-1878 [PMID: 32390698 DOI: 10.3748/wjg.v26.i16.1861] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 6] [Article Influence: 4.5] [Reference Citation Analysis]
68 Yan S. Role of TFEB in Autophagy and the Pathogenesis of Liver Diseases. Biomolecules 2022;12:672. [DOI: 10.3390/biom12050672] [Reference Citation Analysis]
69 Dabravolski SA, Bezsonov EE, Baig MS, Popkova TV, Nedosugova LV, Starodubova AV, Orekhov AN. Mitochondrial Mutations and Genetic Factors Determining NAFLD Risk. Int J Mol Sci 2021;22:4459. [PMID: 33923295 DOI: 10.3390/ijms22094459] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
70 Vasques-Monteiro IML, Souza-Mello V. Coronavirus disease 2019 severity in obesity: Metabolic dysfunction-associated fatty liver disease in the spotlight. World J Gastroenterol 2021; 27(16): 1738-1750 [PMID: 33967554 DOI: 10.3748/wjg.v27.i16.1738] [Cited by in CrossRef: 2] [Article Influence: 2.0] [Reference Citation Analysis]
71 Kjærgaard K, Mikkelsen ACD, Wernberg CW, Grønkjær LL, Eriksen PL, Damholdt MF, Mookerjee RP, Vilstrup H, Lauridsen MM, Thomsen KL. Cognitive Dysfunction in Non-Alcoholic Fatty Liver Disease-Current Knowledge, Mechanisms and Perspectives. J Clin Med 2021;10:673. [PMID: 33572481 DOI: 10.3390/jcm10040673] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
72 Arelaki S, Koletsa T, Sinakos E, Papadopoulos V, Arvanitakis K, Skendros P, Akriviadis E, Ritis K, Germanidis G, Hytiroglou P. Neutrophil extracellular traps enriched with IL-1β and IL-17A participate in the hepatic inflammatory process of patients with non-alcoholic steatohepatitis. Virchows Arch 2022. [PMID: 35503185 DOI: 10.1007/s00428-022-03330-7] [Reference Citation Analysis]
73 Van Campenhout S, Tilleman L, Lefere S, Vandierendonck A, Raevens S, Verhelst X, Geerts A, Van Nieuwerburgh F, Van Vlierberghe H, Devisscher L. Myeloid-specific IRE1alpha deletion reduces tumour development in a diabetic, non-alcoholic steatohepatitis-induced hepatocellular carcinoma mouse model. Metabolism 2020;107:154220. [PMID: 32243868 DOI: 10.1016/j.metabol.2020.154220] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
74 Colino CI, Lanao JM, Gutierrez-Millan C. Targeting of Hepatic Macrophages by Therapeutic Nanoparticles. Front Immunol 2020;11:218. [PMID: 32194546 DOI: 10.3389/fimmu.2020.00218] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 10.0] [Reference Citation Analysis]
75 Niu L, Geyer PE, Gupta R, Santos A, Meier F, Doll S, Wewer Albrechtsen NJ, Klein S, Ortiz C, Uschner FE, Schierwagen R, Trebicka J, Mann M. Dynamic human liver proteome atlas reveals functional insights into disease pathways. Mol Syst Biol 2022;18:e10947. [PMID: 35579278 DOI: 10.15252/msb.202210947] [Reference Citation Analysis]
76 Masoodi M, Gastaldelli A, Hyötyläinen T, Arretxe E, Alonso C, Gaggini M, Brosnan J, Anstee QM, Millet O, Ortiz P, Mato JM, Dufour JF, Orešič M. Metabolomics and lipidomics in NAFLD: biomarkers and non-invasive diagnostic tests. Nat Rev Gastroenterol Hepatol 2021. [PMID: 34508238 DOI: 10.1038/s41575-021-00502-9] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
77 Mohammed A, Paranji N, Chen PH, Niu B. COVID-19 in Chronic Liver Disease and Liver Transplantation: A Clinical Review. J Clin Gastroenterol 2021;55:187-94. [PMID: 33394628 DOI: 10.1097/MCG.0000000000001481] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
78 Diaz Soto MP, Lim JK. Evaluating the Therapeutic Potential of Cenicriviroc in the Treatment of Nonalcoholic Steatohepatitis with Fibrosis: A Brief Report on Emerging Data. Hepat Med 2020;12:115-23. [PMID: 32884369 DOI: 10.2147/HMER.S230613] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
79 Lambrecht J, Tacke F. Controversies and Opportunities in the Use of Inflammatory Markers for Diagnosis or Risk Prediction in Fatty Liver Disease. Front Immunol 2020;11:634409. [PMID: 33633748 DOI: 10.3389/fimmu.2020.634409] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
80 Francque SM, Marchesini G, Kautz A, Walmsley M, Dorner R, Lazarus JV, Zelber-Sagi S, Hallsworth K, Busetto L, Frühbeck G, Dicker D, Woodward E, Korenjak M, Willemse J, Koek GH, Vinker S, Ungan M, Mendive JM, Lionis C. Non-alcoholic fatty liver disease: A patient guideline. JHEP Rep 2021;3:100322. [PMID: 34693236 DOI: 10.1016/j.jhepr.2021.100322] [Reference Citation Analysis]
81 Kwon D, Kim SH, Son SW, Seo J, Jeong TB, Kim KM, Jung JC, Jung MS, Lee YH, Jung YS. Germinated Soybean Embryo Extract Ameliorates Fatty Liver Injury in High-Fat Diet-Fed Obese Mice. Pharmaceuticals (Basel) 2020;13:E380. [PMID: 33187321 DOI: 10.3390/ph13110380] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
82 Tacke F, Weiskirchen R. Non-alcoholic fatty liver disease (NAFLD)/non-alcoholic steatohepatitis (NASH)-related liver fibrosis: mechanisms, treatment and prevention. Ann Transl Med 2021;9:729. [PMID: 33987427 DOI: 10.21037/atm-20-4354] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
83 Jensen-Cody SO, Potthoff MJ. Hepatokines and metabolism: Deciphering communication from the liver. Mol Metab 2021;44:101138. [PMID: 33285302 DOI: 10.1016/j.molmet.2020.101138] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 3.5] [Reference Citation Analysis]
84 Heldens A, Lefere S. MD2 AMP(K)s up the link between lipid accumulation and inflammation in NAFLD. Clin Transl Med 2022;12:e832. [PMID: 35452173 DOI: 10.1002/ctm2.832] [Reference Citation Analysis]
85 Xu L, Liu W, Bai F, Xu Y, Liang X, Ma C, Gao L. Hepatic Macrophage as a Key Player in Fatty Liver Disease. Front Immunol 2021;12:708978. [PMID: 34956171 DOI: 10.3389/fimmu.2021.708978] [Reference Citation Analysis]
86 Heyens LJM, Busschots D, Koek GH, Robaeys G, Francque S. Liver Fibrosis in Non-alcoholic Fatty Liver Disease: From Liver Biopsy to Non-invasive Biomarkers in Diagnosis and Treatment. Front Med (Lausanne) 2021;8:615978. [PMID: 33937277 DOI: 10.3389/fmed.2021.615978] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
87 Yi Y. Regulatory Roles of Caspase-11 Non-Canonical Inflammasome in Inflammatory Liver Diseases. IJMS 2022;23:4986. [DOI: 10.3390/ijms23094986] [Reference Citation Analysis]
88 Vranić L, Radovan A, Poropat G, Mikolašević I, Milić S. Non-Alcoholic Fatty Liver Disease and COVID-19-Two Pandemics Hitting at the Same Time. Medicina (Kaunas) 2021;57:1057. [PMID: 34684094 DOI: 10.3390/medicina57101057] [Reference Citation Analysis]
89 Yao L, Wang Y, Shi J, Liu Y, Guo H, Yang X, Liu Y, Ma J, Li D, Wang Z, Li Z, Luo Q, Fu J, Zhang Q, Qu G, Wang Y, Jiang G. Toxicity of Tetrabromobisphenol A and Its Derivative in the Mouse Liver Following Oral Exposure at Environmentally Relevant Levels. Environ Sci Technol 2021;55:8191-202. [PMID: 34086441 DOI: 10.1021/acs.est.1c01726] [Reference Citation Analysis]
90 Singanayagam A, Triantafyllou E. Macrophages in Chronic Liver Failure: Diversity, Plasticity and Therapeutic Targeting. Front Immunol 2021;12:661182. [PMID: 33868313 DOI: 10.3389/fimmu.2021.661182] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
91 Corrie L, Gulati M, Vishwas S, Kapoor B, Singh SK, Awasthi A, Khursheed R. Combination therapy of curcumin and fecal microbiota transplant: Potential treatment of polycystic ovarian syndrome. Med Hypotheses 2021;154:110644. [PMID: 34332209 DOI: 10.1016/j.mehy.2021.110644] [Reference Citation Analysis]
92 Zhu Y, Ruan S, Shen H, Guan Q, Zhai L, Yang Y. Oridonin regulates the polarized state of Kupffer cells to alleviate nonalcoholic fatty liver disease through ROS-NF-κB. Int Immunopharmacol 2021;101:108290. [PMID: 34717194 DOI: 10.1016/j.intimp.2021.108290] [Reference Citation Analysis]
93 Sun S, Gu Y, Wang J, Chen C, Han S, Che H. Effects of Fatty Acid Oxidation and Its Regulation on Dendritic Cell-Mediated Immune Responses in Allergies: An Immunometabolism Perspective. J Immunol Res 2021;2021:7483865. [PMID: 34423053 DOI: 10.1155/2021/7483865] [Reference Citation Analysis]
94 Mani I, Alexopoulou A. Recent challenges facing patients with preexisting chronic liver disease in the era of the COVID-19 pandemic. Ann Gastroenterol 2021;34:625-33. [PMID: 34475732 DOI: 10.20524/aog.2021.0628] [Reference Citation Analysis]